The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JC.2004-0019PMID 15292331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells*

  2004cited by this paper
• Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome.

  2003cited by this paper
• Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome

  2003cited by this paper
• Von Willebrand factor, platelets and endothelial cell interactions

  2003cited by this paper
• Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.

  2003cited by this paper
• Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.

  2003cited by this paper
• C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.

  2003cited by this paper
• Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress

  2002cited by this paper
• Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.

  2002cited by this paper
• Metformin: An Update

  2002cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper
• Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  2002cited by this paper
• The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism.

  2002cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.

  2002cited by this paper
• Improved endothelial function with metformin in type 2 diabetes mellitus.

  2001cited by this paper
• Angiotensin, fibrinolysis, and vascular homeostasis.

  2001cited by this paper
• Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes.

  2001cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Metformin: intrinsic vasculoprotective properties.

  2000cited by this paper
• Effect of four‐week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes

  2000cited by this paper
• Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study.

  2000cited by this paper
• The role of TNFα and TNF receptors in obesity and insulin resistance

  1999cited by this paper
• The role of TNFalpha and TNF receptors in obesity and insulin resistance.

  1999cited by this paper
• C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

  1999cited by this paper
• Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.

  1999cited by this paper
• Elevated serum TNF‐α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes.

  1999cited by this paper
• Atherosclerosis is an Inflammatory Disease

  1998cited by this paper
• Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.

  1998cited by this paper
• Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

  1998cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.

  1997cited by this paper
• The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes

  1996cited by this paper
• Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups

  1993cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• Spectrophotometry of proline in plasma and urine.

  1972cited by this paper

• Metformin Impact on Maternal and Infant Cardiometabolic Health (MIMICH), an open-label randomised controlled trial, and Metformin Impact on Maternal and Cardiometabolic Health After Pregnancy (MIMICH II)

  2025cites this paper
• Metformin’s Overall Effectiveness and Combined Action with Lifestyle Interventions in Preventing Type-2 Diabetes Mellitus in High-Risk Metformin-Naïve Patients: An Updated Systematic Review and Meta-Analysis of Published RCTs

  2025cites this paper
• Safety and tolerability of metformin in overweight and obese patients with dengue: An open-label clinical trial (MeDO)

  2025cites this paper
• The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials

  2024cites this paper
• The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity.

  2024cites this paper
• Synergistic Effects of L-Arginine and Metformin on Oxidative Stress, Inflammation and Glucometabolic Enzymes in Diabetic Rats

  2024cites this paper
• Effects of ibuprofen in the ZDF rat model of type 2 diabetes

  2024cites this paper
• Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road

  2024cites this paper
• Development of Biotinylated Liposomes Encapsulating Metformin for Therapeutic Targeting of Inflammation-Based Diseases

  2024cites this paper
• Novel therapeutic and diagnostic approaches for preeclampsia

  2023cites this paper
• High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice

  2023cites this paper
• High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice

  2023cites this paper
• Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes.

  2022cites this paper
• Effect of metformin treatment on inflammatory markers in type 2 diabetes mellitus—A systematic review and meta-analysis

  2022influential citation
• Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.

  2022cites this paper
• Effect of nitric oxide-cyclic GMP-K+ channels pathway blockers, naloxone and metformin on the antinociception induced by the diuretic pamabrom.

  2022cites this paper
• Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria

  2022cites this paper
• Structural Comparison of Sulfonamide-Based Derivatives That Can Improve Anti-Coagulation Properties of Metformin

  2022cites this paper
• Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium

  2022cites this paper
• The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon

  2021cites this paper
• Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2021cites this paper
• Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function

  2021cites this paper
• Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes

  2020cites this paper
• An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis.

  2020cites this paper
• AMPK, Mitochondrial Function, and Cardiovascular Disease

  2020cites this paper
• Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases

  2020cites this paper
• The effects of sevelamer carbonate on blood glucose and inflammatory factors in patients with diabetic kidney disease; a controlled clinical trial

  2020cites this paper
• Care of the Diabetic Woman Undergoing Medically Assisted Reproduction

  2020cites this paper
• Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials

  2020cites this paper
• Immunometabolic cross-talk in the inflamed heart

  2019influential citation
• Metformin : a pharmacological approach integrating hyperinsulinemia and breast cancer at the molecular , cellular and clinical levels *

  2019cites this paper
• Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism

  2019cites this paper
• Efecto antinociceptivo y antiinflamatorio de la metformina en modelos experimentales en ratón

  2019cites this paper
• Metformin: time to review its role and safety in chronic kidney disease

  2019cites this paper
• Regulating Inflammatory Cytokines in the Diabetic Heart

  2019cites this paper
• High fat-induced inflammation in vascular endothelium can be improved by Abelmoschus esculentus and metformin via increasing the expressions of miR-146a and miR-155

  2019cites this paper
• Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

  2019cites this paper
• Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes

  2019cites this paper
• Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis

  2018cites this paper
• Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial

  2018cites this paper
• Metformin Inhibits Chemokine Expression Through the AMPK/NF-κB Signaling Pathway

  2018cites this paper
• The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives

  2018cites this paper
• Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.

  2018cites this paper
• Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin

  2018cites this paper
• Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics

  2017cites this paper
• Effect of Garlic (Allium Sativum) on Blood Glucose Level in Type 2 Diabetes Mellitus Patients Treated with Metformin

  2017cites this paper
• Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

  2017cites this paper
• Metformin Inhibits Porphyromonas gingivalis Lipopolysaccharide‐Influenced Inflammatory Response in Human Gingival Fibroblasts via Regulating Activating Transcription Factor‐3 Expression

  2017cites this paper
• Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials

  2017cites this paper
• Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug.

  2016cites this paper
• Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications

  2016influential citation
• AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway.

  2016cites this paper
• THE EFFECT OF DHAWALSAN-1 (CURANGA FEL-TERRAE [LOUR.]) EXTRACT VERSUS METFORMIN ON THE METABOLIC AND INFLAMMATORY CHARACTERISTICS OF PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS Research Article

  2016cites this paper
• Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart.

  2016cites this paper
• Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

  2016cites this paper
• Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes

  2016cites this paper
• Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

  2016cites this paper
• Evaluation of Cardioprotective Effect of Metformin in Isoproterenol Induced Myocardial Injury in Rats

  2016cites this paper
• Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.

  2015cites this paper
• Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial.

  2015cites this paper
• Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease

  2015cites this paper
• Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy

  2015cites this paper
• The Cellular and Molecular Basis of Translational Immunometabolism.

  2015cites this paper
• Metformin Suppresses Lipopolysaccharide (LPS)-induced Inflammatory Response in Murine Macrophages via Activating Transcription Factor-3 (ATF-3) Induction*

  2014cites this paper
• Paradoxic effects of metformin on endothelial cells and angiogenesis

  2014cites this paper
• Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene

  2014cites this paper
• Regulation of macrophage inflammatory signaling pathways by AMP-activated protein kinase.

  2014cites this paper
• Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

  2014cites this paper
• ANÁLISIS DE LA ACTIVIDAD ANTIINFLAMATORIA Y ANALGÉSICA DE LA METFORMINA EN EL CUADRO AGUDO

  2014cites this paper
• EVALUATION OF POTENTIAL PROTECTIVE EFFECTS OF CURCUMIN VERSUS METFORMIN IN EXPERIMENTALLY-INDUCED METABOLIC SYNDROME IN RATS

  2014cites this paper
• AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6

  2013cites this paper
• Repositioning metformin for cancer prevention and treatment.

  2013cites this paper
• Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three‐dimensional power doppler ultrasonography

  2013cites this paper
• Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase– lowering effects of garlic in patients with type 2 diabetes mellitus with obesity

  2013cites this paper
• Insulin resistance, chronic heart failure and potential treatment

  2013cites this paper
• Metformin: the hidden chronicles of a magic drug.

  2013cites this paper
• AMPK Mediates Endothelial Function Through the Phosphorylation of Nucleolin and PARP-1 - eScholarship

  2013cites this paper
• Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency

  2013cites this paper
• Análisis de la Actividad Antiinflamatoria y Analgésica Aguda de la Metformina Mediante El Test de Formalina

  2012cites this paper
• Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?

  2012cites this paper
• The effect of metformin on insulin resistance and exercise parameters in patients with heart failure

  2012cites this paper
• Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.

  2012cites this paper
• Metformin prevents macrosomia and neonatal morbidity in gestational diabetes

  2012cites this paper
• The role of inflammation in diabetic cardiomyopathy

  2012cites this paper
• [Stroke care in the ICU: general supportive treatment. Experts' recommendations].

  2012cites this paper
• Determinants of increased cardiovascular disease in obesity and metabolic syndrome.

  2011cites this paper
• Traffic exposure in a population with high prevalence type 2 diabetes--do medications influence concentrations of C-reactive protein?

  2011cites this paper
• EFECTO DE LA METFORMINA EN LA FUNCIÓN SISTOLICA Y DIASTOLICA DEL VENTRÍCULO IZQUIERDO VALORADO POR ECOCARDIOGRAMA EN PACIENTES CON SÍNDROME METABÓLICO

  2011cites this paper
• Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects.

  2011cites this paper
• Changes of Body Weight and Inflammatory Markers after 12-Week Intervention Trial: Results of a Double-Blind, Placebo-Control Pilot Study

  2011cites this paper
• Metformin restores endothelial function in aorta of diabetic rats

  2011cites this paper
• Metformin: a pharmacological approach integrating hyperinsulinemia breast cáncer at the molecular, cellular clinical levels*

  2010cites this paper
• Antidepressant Medicine Use and Risk of Developing Diabetes During the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

  2010cites this paper
• Metformin Attenuates Production of Nitric Oxide in Response to Lipopolysaccharide by Inhibiting MyD88-Independent Pathway

  2010cites this paper
• Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

  2010cites this paper
• Review: Metformin: Potential benefits and use in chronic kidney disease

  2010cites this paper
• Measure for measure: consequences, detection and treatment of hyperglycaemia

  2010cites this paper
• Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4.

  2010cites this paper
• The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.

  2010cites this paper
• Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

  2010cites this paper